LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Ouvert

4.01 -0.74

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.89

Max

4.09

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	-619K -38M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+76.77% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-5.7M 289M
Ouverture précédente	4.75
Clôture précédente	4.01

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 mai 2026, 21:33 UTC

Résultats

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mai 2026, 21:00 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mai 2026, 20:18 UTC

Résultats

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mai 2026, 21:29 UTC

Actions en Tendance

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mai 2026, 21:08 UTC

Résultats

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mai 2026, 21:02 UTC

Résultats

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mai 2026, 20:59 UTC

Acquisitions, Fusions, Rachats

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mai 2026, 20:55 UTC

Résultats

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 mai 2026, 20:48 UTC

Résultats

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mai 2026, 20:45 UTC

Résultats

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mai 2026, 20:34 UTC

Acquisitions, Fusions, Rachats

Webster Financial Stockholders Approve Sale to Banco Santander

27 mai 2026, 20:32 UTC

Résultats

Acquisitions, Fusions, Rachats

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mai 2026, 20:32 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mai 2026, 20:32 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mai 2026, 20:30 UTC

Résultats

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mai 2026, 20:30 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mai 2026, 20:22 UTC

Résultats

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:16 UTC

Résultats

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:13 UTC

Résultats

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mai 2026, 20:13 UTC

Résultats

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mai 2026, 20:13 UTC

Résultats

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mai 2026, 20:12 UTC

Résultats

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mai 2026, 20:12 UTC

Résultats

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

76.77% hausse

Prévisions sur 12 Mois

Moyen 7 USD 76.77%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.